Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.50 |
| ▸ | DRD3 | P35462 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113163 | 0.87 | DRD2 (0.51) | DRD2DRD3KDM4EMAPTRAD52 | |
| SCHEMBL16463118 | 0.81 | ADRA2C (0.43) | DRD2DRD3KDM4EMAPTRAD52 | |
| SCHEMBL3034689 | 0.79 | MAPT (0.49) | KDM4EMAPTPOLBGAAMAPK1 | |
| SCHEMBL3584990 | 0.79 | ALDH1A1 (0.47) | DRD2DRD3KDM4EMAPTRAD52 | |
| SCHEMBL4173801 | 0.79 | DRD2 (0.45) | DRD2DRD3KDM4EMAPTRAD52 | |
| SCHEMBL3595550 | 0.77 | DRD2 (0.55) | DRD2DRD3KDM4EMAPTRAD52 | |
| SCHEMBL3584991 | 0.77 | ALDH1A1 (0.41) | DRD2DRD3KDM4EMAPTRAD52 | |
| SCHEMBL188362 | 0.76 | ADRA2C (0.42) | DRD2DRD3KDM4EMAPTRAD52 | |
| SCHEMBL3582056 | 0.76 | ADRA2C (0.39) | DRD2DRD3KDM4EMAPTRAD52 | |
| SCHEMBL3593318 | 0.76 | ADRA2C (0.39) | DRD2DRD3KDM4EMAPTRAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682076-A4 | INHIBITORS OF CORONAVIRUS PROTEASE AND METHODS OF USE THEREOF | FULCRUM PHARMACEUTICALS INC (US) | 2008-02-06 | — | — | EP | claimed |
| EP-1682076-A2 | INHIBITORS OF CORONAVIRUS PROTEASE AND METHODS OF USE THEREOF | Fulcrum Pharmaceuticals, Inc. (US) | 2006-07-26 | — | — | EP | claimed |
| US-20050267071-A1 | Inhibitors of coronavirus protease and methods of use thereof | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | US | claimed |
| WO-2005041904-A2 | INHIBITORS OF CORONAVIRUS PROTEASE AND METHODS OF USE THEREOF | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | claimed |
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| CN-101516888-A | Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use | NOVARTIS AG (CH) | 2009-08-26 | — | — | CN | disclosed |
| EP-1682076-A4 | INHIBITORS OF CORONAVIRUS PROTEASE AND METHODS OF USE THEREOF | FULCRUM PHARMACEUTICALS INC (US) | 2008-02-06 | — | — | EP | disclosed |
| EP-1682076-A2 | INHIBITORS OF CORONAVIRUS PROTEASE AND METHODS OF USE THEREOF | Fulcrum Pharmaceuticals, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050267071-A1 | Inhibitors of coronavirus protease and methods of use thereof | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | US | disclosed |
| WO-2005041904-A2 | INHIBITORS OF CORONAVIRUS PROTEASE AND METHODS OF USE THEREOF | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| EP-0773937-A1 | NOVEL ARYL PIPERAZINE-DERIVED PIPERAZIDE DERIVATIVES, METHODS FOR THEIR PREPARATION, THEIR USE AS DRUGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | PIERRE FABRE MEDICAMENT (FR) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996002525-A1 | NOVEL ARYL PIPERAZINE-DERIVED PIPERAZIDE DERIVATIVES, METHODS FOR THEIR PREPARATION, THEIR USE AS DRUGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | PIERRE FABRE MEDICAMENT (FR) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267071-A1 | Inhibitors of coronavirus protease and methods of use thereof | ACE, ACE2, CTRL | DRD2 4682/4885DRD3 4255/4885KDM4E 2334/4885 |
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | DRD2 4782/4885DRD3 4637/4885KDM4E 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.